Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and Jan
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
02:19pm, Wednesday, 11'th Mar 2026
Regenxbio Inc. (NASDAQ: RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
12:00pm, Wednesday, 11'th Mar 2026
Regenxbio said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed c
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
11:45am, Wednesday, 11'th Mar 2026
Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 ye
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
09:36am, Wednesday, 11'th Mar 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquir
Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX
09:00am, Wednesday, 11'th Mar 2026
NEW YORK, March 11, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit. CLASS DEFINITION
New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9,
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
04:00pm, Tuesday, 10'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP examines the adequacy of REGENXBIO, Inc.'s (NASDAQ: RGNX) risk disclosures to investors during the period between February 9, 2022 and January 27, 2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX). Such inv
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:30am, Tuesday, 10'th Mar 2026
LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio”
Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
09:00am, Tuesday, 10'th Mar 2026
NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class pe
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquir
New York, New York--(Newsfile Corp. - March 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 20
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
02:00pm, Monday, 09'th Mar 2026
New class action for REGENXBIO Inc. (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/14/2026.
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
01:31pm, Monday, 09'th Mar 2026
LOS ANGELES, March 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that
